B

Beijing Airdoc Technology
2251

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
HK$1.17B
EV
HK$517.26M
Shares Outstanding
102.51M
Beta
0.74
Industry
Medical - Healthcare Information Services

Wall Street View

Analyst Rating
BUY
Analyst Target Price
Number of Analysts
1
P/E 2025E
-
P/Revenue 2025E
5.29x

Historical 3Y Growth Rate

Revenue
EPS
Operating Cash Flow
Free Cash Flow

Forecasted 3Y Growth Rate

Revenue
EPS
Operating Cash Flow
Free Cash Flow

Margins & Returns

Gross Margin 2025E
46.90%
Net Profit Margin 2025E
-59.80%
ROE 2025E
-9.80%
ROCE 2024
-18.19%

Dividends

DPS 2025E
-
Payout Ratio 2025E
-
Div. Yield 2025E
-
DPS Last 3Y CAGR

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Beijing Airdoc Technology Co., Ltd.

gainify

B

Beijing Airdoc Technology Co., Ltd.

2251

Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, A...

Sector

Healthcare

Industry

Medical - Healthcare Information Services

CEO

Zhang, Dalei

Employees

193

IPO Date

2021-11-05

Headquarters

Deputy Building, Building 2, Room 21, 4th Floor, A2 Yard West Third Ring North Road, Haidian District, Beijing 100089, China

📊 Stock Price & Performance

The last closing price of Beijing Airdoc Technology (2251) is HK$11.43, reflecting a +1.69% change from the prior session. Last updated: January 1, 2026 at 3:01 AM Eastern Time

Review the recent 2251 stock performance trends:Past 1 Month: Beijing Airdoc Technology (2251) shares have -3.46%.Past 3 Months: The stock has -18.06%.Past 6 Months: 2251 shares have -10.42%. Last updated: December 31, 2025 at 11:58 PM Eastern Time

Over the last year, Beijing Airdoc Technology (2251) has established a 52-week price range between a high of HK$16.00 and a low of HK$10.00. This metric is essential for assessing the stock's annual volatility. Last updated: December 31, 2025 at 11:58 PM Eastern Time

Beijing Airdoc Technology (2251) is considered a medium volatility stock. It has a beta of 0.74, which means it typically moves 0.74 times as much as the broader market. Over the past 52 weeks, 2251 has traded within a HK$10.00 – HK$16.00 range. Last updated: December 31, 2025 at 11:58 PM Eastern Time

Based on current 2251 analyst forecasts and market assumptions, the consensus price target for Beijing Airdoc Technology (2251) is HK$13.14 for 2027. Relative to the current price of HK$11.43, this implies a positive upside of +14.94%. Price targets reflect forward-looking estimates based on information available at the time and are inherently subject to change as underlying assumptions, company fundamentals, or market conditions evolve. Last updated: January 1, 2026 at 3:01 AM Eastern Time

💰 Financial Metrics & Reports

The current Beijing Airdoc Technology (2251) market capitalization is approximately HK$1.17B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Beijing Airdoc Technology's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:58 PM Eastern Time

In the most recently reported quarter, Beijing Airdoc Technology (2251) generated HK$45.87M in revenue, representing a -8.90% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 3:13 AM Eastern Time

In the most recently reported fiscal year, Beijing Airdoc Technology (2251) generated net income of HK$-0.27B, compared with HK$-0.15B in the prior fiscal year, representing a -86.19% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of HK$-0.13B. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 3:13 AM Eastern Time

According to its latest quarterly filing, Beijing Airdoc Technology (2251) reported EBITDA of HK$-3.75M, representing a +92.26% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 3:13 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.01x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: January 1, 2026 at 3:13 AM Eastern Time

Based on the latest available data, Beijing Airdoc Technology (2251) is currently trading at a last twelve months (LTM) P/E ratio of -6.09x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 3:13 AM Eastern Time

📅 Earnings & Dividends

In the most recently reported quarter, Beijing Airdoc Technology (2251) revenue was HK$45.87M. Earnings per share (EPS) for the quarter were HK$-0.01. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 3:13 AM Eastern Time

Beijing Airdoc Technology (2251) does not currently pay a dividend. Over the last twelve months (LTM), the company paid HK$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 3:13 AM Eastern Time

📈 Analyst Information

Analyst assessments of whether Beijing Airdoc Technology (2251) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: HK$11.43Consensus price target: HK$13.14Implied return: +14.94% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: January 1, 2026 at 3:13 AM Eastern Time

Based on the latest available analyst coverage, Beijing Airdoc Technology (2251) currently carries a Buy consensus rating. Analysts' average 2251 price target is HK$13.14. Relative to the current share price of HK$11.43, this suggests a potential price change of approximately +14.94%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 3:13 AM Eastern Time

Like other publicly traded stocks, Beijing Airdoc Technology (2251) shares are bought and sold on stock exchanges such as SEHK and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Beijing Airdoc Technology (2251) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

ℹ️ Company Information

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 2251 to your watchlist.

Beijing Airdoc Technology trades under the ticker symbol 2251 on the SEHK stock exchange. The ticker 2251 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Beijing Airdoc Technology (2251) employs approximately 193 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: December 31, 2025 at 11:58 PM Eastern Time

Beijing Airdoc Technology (2251) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Beijing Airdoc Technology (2251) stock peers based on overlapping products, services, and competitive dynamics:BrainAurora Medical Technology (6681)TOWA Hi SYSTEM (4172)MeVis Medical Solutions (M3V)Mach7 Technologies (M7T)Beamtree Holdings (BMT)Physitrack (PTRK)DarioHealth (DRIO) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Beijing Airdoc Technology.

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2026 Gainify. All rights reserved.